{"classes":[{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 3"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 5"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 8"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 9"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 10"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"title":"Cycle 11"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"Blood samples were collected for PK analysis. PK parameter was determined using standard non-compartmental methods.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with RRMM received belantamab mafodotin as dose of 2.5mg/kg via IV infusion on Day 1 of every 21-day cycle (Q3W) maximum up to disease progression. Bortezomib was administered subcutaneously (SC) as 1.3 mg/meter\\^2 (m\\^2) on Day 1, Day 4, Day 8, and Day 11 of every 21-day cycle maximum up to 8 cycles. Dexamethasone was administered orally as dose of 20 mg on Day 1, Day 2, Day 4, Day 5, Day 8, Day 9, Day 11, and Day 12 of every 21-day cycle maximum up to 8 cycles.","id":"OG000","title":"Main Study - Part 2: ArmA-Belantamab Mafodotin 2.5 mg/kg + Bortezomib and Dexamethasone (Bor/Dex)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Pharmacokinetic population. Due to shorter half-life of cys-mcMMAF, the concentration values were below the Lower Limit of Quantification (LLOQ). Hence, Ctrough values were not determined.","reportingStatus":"POSTED","timeFrame":"Cycle 3, Cycle 5, Cycle 8, Cycle 9, Cycle 10 and Cycle 11","title":"Part 2: Arm A: Ctrough Following Repeat Dose Administration of Belantamab Mafodotin (Cys-mcMMAF)","type":"SECONDARY","unitOfMeasure":"pg/mL"}